Design and synthesis of a novel series of bicyclic heterocycles as potent γ-secretase modulators.

The design and the synthesis of several chemical subclasses of imidazole containing γ-secretase modulators (GSMs) is described. Conformational restriction of pyridone 4 into bicyclic pyridone isosteres has led to compounds with high in vitro and in vivo potency. This has resulted in the identification of benzimidazole 44a as a GSM with low nanomolar potency in vitro. In mouse, rat, and dog, this compound displayed the typical γ-secretase modulatory profile by lowering Aβ42 and Aβ40 levels combined with an especially pronounced increase in Aβ38 and Aβ37 levels while leaving the total levels of amyloid peptides unchanged.

[1]  A. Szewczak,et al.  Triazoloamides as potent γ-secretase modulators with reduced hERG liability. , 2012, Bioorganic & medicinal chemistry letters.

[2]  Gregory W. Kauffman,et al.  Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active γ-secretase modulators. , 2012, Bioorganic & medicinal chemistry letters.

[3]  B. de Strooper,et al.  The mechanism of γ-Secretase dysfunction in familial Alzheimer disease , 2012, The EMBO journal.

[4]  Y. Shitaka,et al.  Differential Effects between γ-Secretase Inhibitors and Modulators on Cognitive Function in Amyloid Precursor Protein-Transgenic and Nontransgenic Mice , 2012, The Journal of Neuroscience.

[5]  F. Panza,et al.  Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease , 2012, Expert opinion on drug discovery.

[6]  Arup K. Ghose,et al.  Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery , 2011, ACS chemical neuroscience.

[7]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[8]  K. Rhodes,et al.  Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable γ-Secretase Modulator. , 2011, ACS medicinal chemistry letters.

[9]  J. D. Elliott,et al.  Pyridine-derived γ-secretase modulators. , 2011, Bioorganic & medicinal chemistry letters.

[10]  M. Hann.  Molecular obesity, potency and other addictions in drug discovery , 2011 .

[11]  N. Ramsden,et al.  Chronic treatment with a novel γ‐secretase modulator, JNJ‐40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease , 2011, British journal of pharmacology.

[12]  Lynn A. Hyde,et al.  Discovery of a Potent Pyrazolopyridine Series of γ-Secretase Modulators. , 2011, ACS medicinal chemistry letters.

[13]  Daniel Oehlrich,et al.  γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs. , 2011, Journal of medicinal chemistry.

[14]  Gregory W. Kauffman,et al.  Novel γ-secretase modulators: a review of patents from 2008 to 2010 , 2011, Expert opinion on therapeutic patents.

[15]  Lynn A. Hyde,et al.  Discovery of fused 5,6-bicyclic heterocycles as γ-secretase modulators. , 2011, Bioorganic & medicinal chemistry letters.

[16]  A. Szewczak,et al.  Quinazolinones as γ-secretase modulators. , 2011, Bioorganic & medicinal chemistry letters.

[17]  Xulun Zhang,et al.  Modulation of γ-Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease , 2010, Neuron.

[18]  Petra Schneider,et al.  Exploring the chemical space of gamma-secretase modulators. , 2010, Trends in pharmacological sciences.

[19]  Lynn A. Hyde,et al.  The Discovery of Pyridone and Pyridazone Heterocycles as γ-Secretase Modulators. , 2010, ACS medicinal chemistry letters.

[20]  Simone Braggio,et al.  Assessing brain free fraction in early drug discovery , 2010, Expert opinion on drug metabolism & toxicology.

[21]  Gregory R J Thatcher,et al.  Selective modulation of amyloid‐β peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Aβ levels , 2009, Journal of neurochemistry.

[22]  Y. Ihara,et al.  γ-Secretase: Successive Tripeptide and Tetrapeptide Release from the Transmembrane Domain of β-Carboxyl Terminal Fragment , 2009, The Journal of Neuroscience.

[23]  R. Martone,et al.  Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. , 2009, Journal of medicinal chemistry.

[24]  T. Tomita.  Secretase inhibitors and modulators for Alzheimer’s disease treatment , 2009, Expert review of neurotherapeutics.

[25]  H. Jacobsen,et al.  Alzheimer's disease: from pathology to therapeutic approaches. , 2009, Angewandte Chemie.

[26]  B. de Strooper,et al.  Structure and function of gamma-secretase. , 2009, Seminars in cell & developmental biology.

[27]  A. W. Garofalo.  Patents targeting γ-secretase inhibition and modulation for the treatment of Alzheimer's disease: 2004 – 2008 , 2008 .

[28]  Ayman El-Kattan,et al.  Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. , 2007, Expert opinion on drug metabolism & toxicology.

[29]  Guolan Dou,et al.  A Novel and Efficient Synthesis of 2-Aryl-2H-indazoles via SnCl2-Mediated Cyclization of 2-Nitrobenzylamines , 2007 .

[30]  D. Small,et al.  Alois Alzheimer and Alzheimer's disease: a centennial perspective , 2006, Journal of neurochemistry.

[31]  R. Ho,et al.  MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. , 2006, Journal of pharmaceutical sciences.

[32]  Richard M Walmsley,et al.  High-specificity and high-sensitivity genotoxicity assessment in a human cell line: validation of the GreenScreen HC GADD45a-GFP genotoxicity assay. , 2006, Mutation research.

[33]  R. Batey,et al.  Parallel synthesis of a library of benzoxazoles and benzothiazoles using ligand-accelerated copper-catalyzed cyclizations of ortho-halobenzanilides. , 2006, The Journal of organic chemistry.

[34]  Dominic M. Walsh,et al.  Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease , 2004, Neuron.

[35]  L A Hansen,et al.  The importance of neuritic plaques and tangles to the development and evolution of AD , 2004, Neurology.

[36]  E. Kantharaj,et al.  Simultaneous measurement of drug metabolic stability and identification of metabolites using ion-trap mass spectrometry. , 2003, Rapid communications in mass spectrometry : RCM.

[37]  Y. Ge,et al.  A Proximal Gene Promoter Region for the β‐Amyloid Precursor Protein Provides a Link between Development, Apoptosis, and Alzheimer's Disease , 2003, Annals of the New York Academy of Sciences.

[38]  M. S. South,et al.  Synthesis of 2-pyridones as tissue factor VIIa inhibitors , 2003 .

[39]  D. Zewge,et al.  Amination of aryl halides using copper catalysis , 2001 .

[40]  J. Dressman,et al.  In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[41]  C. Cotman,et al.  Evolution in the Conceptualization of Dementia and Alzheimer’s Disease: Greco-Roman Period to the 1960s , 1998, Neurobiology of Aging.

[42]  E. Zeiger,et al.  Comparison of responses of base-specific Salmonella tester strains with the traditional strains for identifying mutagens: the results of a validation study. , 1998, Mutation research.

[43]  G. Petrillo,et al.  A novel approach to 1H-indazoles via arylazosulfides , 1994 .

[44]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[45]  S. Ranganathan,et al.  Correlations between the solvent hydrogen bond acceptor parameter β and the calculated molecular electrostatic potential , 1991 .

[46]  M. Venuti,et al.  Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline. , 1988, Journal of medicinal chemistry.

[47]  V. Stella,et al.  Low-melting phenytoin prodrugs as alternative oral delivery modes for phenytoin: a model for other high-melting sparingly water-soluble drugs. , 1983, Journal of pharmaceutical sciences.

[48]  María Lourdes Linares,et al.  Scaffold hopping from pyridones to imidazo[1,2-a]pyridines. New positive allosteric modulators of metabotropic glutamate 2 receptor. , 2010, Bioorganic & medicinal chemistry letters.

[49]  F. Panza,et al.  Disease-Modifying Approach to the Treatment of Alzheimer’s Disease , 2009, Drugs & aging.

[50]  I. Peretto,et al.  Gamma-secretase modulation and its promise for Alzheimer's disease: a medicinal chemistry perspective. , 2008, Current topics in medicinal chemistry.

[51]  Weiming Xia,et al.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.